We Are Crinetics
Crinetics is a pharmaceutical company founded in endocrinology research. Our intense focus is on developing much-needed therapies for people with rare endocrine diseases. For us, it’s all about these underserved patients, who are eager to find therapies that provide effective disease control and bring more simplicity to their lives.
To better achieve these goals, we also partner with endocrinologists and other healthcare practitioners to ensure we’re solving real problems for them.
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
| Discovery | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
NANETS 2021
Dose selection for paltusotine, a once-daily, oral, nonpeptide, somatostatin receptor 2 ligand (SST2), for the treatment of patients with carcinoid syndrome (CS)
Paltusotine phase 2 study in carcinoid syndrome
Fill out this form to be contacted by a member of our study team.